Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2083

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Andrea C. Lo, Belinda A. Campbell, Tom Pickles, Christina Aquino-Parsons, Laurie H. Sehn, Joseph M. Connors, Kerry J. Savage

Blood (2020) 136 (8): 1006–1010.

https://doi.org/10.1182/blood.2019004588

Published: 2020

Includes: Supplemental data

Journal Articles

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

Blood (2020) 135 (26): 2365–2374.

https://doi.org/10.1182/blood.2019003877

Published: 2020

Includes: Supplemental data

Journal Articles

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Joachim Yahalom, Bouthaina Shbib Dabaja, Umberto Ricardi, Andrea Ng, N. George Mikhaeel, Ivan R. Vogelius, Tim Illidge, Shunan Qi, Andrew Wirth, Lena Specht

Blood (2020) 135 (21): 1829–1832.

https://doi.org/10.1182/blood.2020006028

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

Juan Pablo Alderuccio, Derek Isrow, Isildinha M. Reis, Sunil Girish Iyer, Jessica J. Meshman, Wei Zhao, Francisco Vega, Jennifer R. Chapman, Arnold M. Markoe, Izidore S. Lossos

Blood (2020) 135 (15): 1299–1302.

https://doi.org/10.1182/blood.2019003236

Published: 2020

Includes: Supplemental data

Journal Articles

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Allison Barraclough, Edward Yoo, Chan Y. Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, MD, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, MBBS,FRACP,FRCPA, Stephen Opat, Zoe McQuilten, Erica M. Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes

Blood (2019) 134 (Supplement_1): 3986.

https://doi.org/10.1182/blood-2019-129294

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

Bachar Samra, MD, Guillaume Richard-Carpentier, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Veronica A Guerra, MD, Naval G. Daver, MD, Courtney D. DiNardo, MDMSc, Ghayas C. Issa, MD, Prithviraj Bose, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD

Blood (2019) 134 (Supplement_1): 3834.

https://doi.org/10.1182/blood-2019-125330

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy

Jason N Barreto, PharmD, Carrie A. Thompson, MD, Kristin C. Mara, MS., Amanda G Sierzchulski, PharmD, Ashley L Potter, PharmD, Pritish K Tosh, MD, Andrew H Limper, MD

Blood (2019) 134 (Supplement_1): 4052.

https://doi.org/10.1182/blood-2019-122060

Published: 2019

Journal Articles

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Mattia Novo, Grzegorz Nowakowski, MD, Ivana Micallef, MD, Rebecca L. King, MD, Robert Spinner, MD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Patrick Johnston, MD PhD

Blood (2019) 134 (Supplement_1): 4129.

https://doi.org/10.1182/blood-2019-131378

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)

Jorge Florindez, MD MS, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 4014.

https://doi.org/10.1182/blood-2019-127688

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Cyprien Shyirambere, MD, Rebecca Deboer, MD, Yvan Butera, MD, Caitlin Driscoll, resident, Jean Bosco Bigirimana, Francois Regis Uwizeye, Temidayo Fadelu, MD, Paul H Park, MD, Alan Paciorek, Leslie E. Lehmann, MD, Lawrence N. Shulman, MD

Blood (2019) 134 (Supplement_1): 4053.

https://doi.org/10.1182/blood-2019-130780

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only